Which antifungal agent is the first-line treatment for invasive Mucormycosis?

Explanation

## First-Line Antifungal Therapy for Mucormycosis **Key Point:** Liposomal amphotericin B (L-AmB) is the **gold standard** and first-line agent for invasive Mucormycosis due to superior efficacy and tissue penetration. ### Antifungal Susceptibility Profile | Agent | Mucormycosis | Aspergillosis | Notes | |-------|--------------|---------------|-----------| | **Liposomal Amphotericin B** | **Effective (DOC)** | Effective | High-dose: 10 mg/kg/day IV | | **Voriconazole** | Resistant | Effective (DOC) | Azoles ineffective against Mucor | | **Fluconazole** | Resistant | Moderate | Poor CNS penetration | | **Itraconazole** | Resistant | Alternative | Oral option for maintenance | | **Posaconazole** | Moderate activity | Effective | Second-line for Mucor salvage | **High-Yield:** Mucormycetes are **intrinsically resistant to azoles** (voriconazole, fluconazole, itraconazole) due to differences in fungal ergosterol metabolism. This is a critical distinction from Aspergillus, which is susceptible to voriconazole. ### Treatment Protocol 1. **Induction:** Liposomal amphotericin B 10 mg/kg/day IV for 2–4 weeks 2. **Consolidation/Maintenance:** Posaconazole 300 mg daily (oral) or continue L-AmB if renal function permits 3. **Surgical debridement:** Essential for localized disease (rhinocerebral, cutaneous, pulmonary) **Clinical Pearl:** Early diagnosis and aggressive surgical debridement combined with high-dose amphotericin B are the cornerstones of survival in Mucormycosis. Delay in treatment significantly increases mortality. **Warning:** Do NOT use azoles as monotherapy for Mucormycosis — they will fail. Voriconazole is the drug of choice for Aspergillus, but it is ineffective for Mucor.